Arbutus Biopharma wins partial summary judgment on Moderna defenses; enablement dispute to go to jury
Arbutus Biopharma has achieved a partial summary judgment against Moderna, barring Moderna's obviousness and derivation defenses related to certain patents. While the court ruled in Arbutus's favor on several points including IPR estoppel and issue preclusion, the dispute regarding enablement will proceed to a jury for resolution. This legal development stems from an SEC filing by Arbutus Biopharma Corp (ABUS).
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200-Day Moving Average - Here's What Happened
Arbutus Biopharma (NASDAQ:ABUS) stock briefly traded above its 200-day moving average of $4.28, hitting an intraday high of $4.34 before closing at $4.17. The company has a market capitalization of approximately $802 million and institutional investors hold about 43.8% of its shares. Analyst ratings are mixed, leading to an average "Hold" consensus and a $5.00 price target.
Arbutus Biopharma (ABUS) Patent Invalidated by European Patent O
The European Patent Office has invalidated a key Arbutus Biopharma patent, which benefits Moderna by reducing potential legal challenges in Europe. Arbutus Biopharma, a clinical-stage biopharmaceutical company focused on chronic hepatitis B, faces financial challenges including negative revenue growth and profitability. Despite strong financial strength metrics, investors are advised to consider the company's ongoing patent disputes and sector-specific risks.
ABUS Stock Tumbles on European Patent Revocation
Arbutus Biopharma Corporation's (ABUS) stock fell by 14.04% following the European Patent Office's revocation of a crucial patent, a decision influenced by challenges from Moderna and Merck. This legal setback exacerbates the company's existing financial struggles, which include negative profit margins and a high price-to-sales ratio. Analysts maintain a negative sentiment, citing significant vulnerabilities for ABUS in the competitive biotech landscape.
Market Dynamics Cause Shifts for Arbutus Biopharma
Arbutus Biopharma (ABUS) stock has experienced an 11.05% decline amidst market uncertainty regarding strategic shifts and challenges. Despite financial hurdles, the company shows promise through innovative pursuits, strong partnerships, and controlled debt, aiming for wider global reach. Investors remain cautiously optimistic, focusing on risk management and monitoring economic indicators to navigate competitive pressures and ensure sustainable growth.
Arbutus Biopharma (ABUS) Patent Revocation Leads to 18% Stock Crash
Arbutus Biopharma (ABUS) experienced an 18% stock crash after the European Patent Office revoked its EP 2279254 patent on January 15. Despite this, Arbutus plans to appeal the decision and asserts it will not impact ongoing patent infringement cases against Moderna in other regions. While Moderna's stock rose, and Merck's fell, retail sentiment on Stocktwits saw the ABUS dip as a buying opportunity, indicating mixed views on its future.
Arbutus Biopharma (NASDAQ:ABUS) Shares Gap Down - Here's Why
Arbutus Biopharma (NASDAQ:ABUS) shares gapped down by about 12.9% on Friday, opening at $3.94 after a $4.70 close, with roughly 3.12 million shares traded. The company has a consensus "Hold" rating from analysts with a $5.00 target, despite recent mixed analyst actions including a "Buy" call from Chardan and a downgrade to "Hold" from Wall Street Zen. This decline follows a quarterly earnings report that beat EPS expectations but missed on revenue, with the company remaining unprofitable.
European Patent Office revokes Arbutus Biopharma patent following appeal
The European Patent Office's Board of Appeal has revoked Arbutus Biopharma Corporation's European patent EP 2279254, a decision the company disagrees with and plans to challenge. Despite this, Arbutus does not anticipate the revocation to impact its ongoing patent infringement cases against Moderna, Pfizer, and BioNTech in other jurisdictions like the U.S., Japan, and Canada, citing that the ruling was based on "added matter" which is not applicable there. The company maintains a strong liquidity position, as indicated by InvestingPro data, and has recently reported encouraging clinical data for its hepatitis B treatment despite a third-quarter loss.
Arbutus Biopharma Corp - EPO revokes Arbutus Biopharma's European patent EP 2279254 - SEC filing
The European Patent Office (EPO) has revoked Arbutus Biopharma's European patent EP 2279254, as disclosed in an SEC filing. This development is significant for Arbutus Biopharma, a clinical-stage biopharmaceutical company focused on developing therapies for chronic hepatitis B virus (cHBV) infection. The company's pipeline includes Imdusiran and AB-101.
Hepatitis B Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | Arbutus Biopharma, GSK/Ionis Pharma, Vir Biotech, Dong-A ST Co., Ltd., Barinthus Biotherapeutics, GC Biopharma Corp
The Hepatitis B market is projected to experience significant growth by 2034, driven by increasing prevalence and developing pipeline products. Several key companies are advancing therapies, with Precision BioSciences, Barinthus Biotherapeutics, and YS Biopharma reporting significant clinical trial progress. The report highlights market opportunities in new diagnostic tools and research into conventional therapeutic methods.
Arbutus Biopharma's CFO David Hastings sells shares worth $72,826
David Hastings, the CFO of Arbutus Biopharma (NASDAQ: ABUS), recently sold 34,705 shares of the company's stock at an average price of $2.10 per share, totaling $72,826. This transaction follows other insider selling activities at the company over the past year.
Pharma Patent Trials Loom in 2026 for Wegovy, Covid-Vaccine Tech
Siegmund Gutman, Life Science Litigation Practice Chair at Mintz, was quoted in a Bloomberg Law article discussing major pharmaceutical patent lawsuits scheduled for trial in 2026. He commented on the "huge case" involving Arbutus Biopharma Corp. and Genevant Sciences GmbH seeking royalties from Moderna Inc.'s Spikevax Covid-19 vaccine, highlighting it as a test for older patents against modern validity scrutiny for blockbuster drugs.
Arbutus Biopharma (NASDAQ:ABUS) Share Price Passes Above Two Hundred Day Moving Average - Time to Sell?
Arbutus Biopharma (NASDAQ:ABUS) recently saw its stock price climb above its 200-day moving average, reaching $4.68 with a high of $4.80. Despite this technical strength, analysts remain mixed, with a consensus "Hold" rating and an average price target of $5.00. The company faces fundamental challenges, including a negative net margin and a miss on revenue expectations, despite beating EPS estimates last quarter.
BlackBarn Capital Partners LP Boosts Stock Position in Arbutus Biopharma Corporation $ABUS
BlackBarn Capital Partners LP significantly increased its stake in Arbutus Biopharma Corporation by 11.2% during the second quarter, making it their 15th largest holding with 2.6 million shares valued at $8.045 million. Other institutional investors like Bank of America Corp DE and Adage Capital Partners GP L.L.C. also boosted their holdings. Despite this, analysts have a "Hold" consensus rating for Arbutus Biopharma, with a target price of $5.00.
Arbutus Biopharma Corp Discusses Ongoing Patent Litigation
Arbutus Biopharma Corp (ABUS) provided an update on its patent litigation against Moderna, Pfizer, and BioNTech, asserting infringement on its LNP patents. A U.S. jury trial against Moderna is set for March 2026, with ex-U.S. Moderna cases expected to begin in 2026, and Pfizer/BioNTech litigation awaiting scheduling. The company notes generally favorable Markman rulings in its U.S. cases.
Arbutus Biopharma shares rise as imdusiran data shows promising results
Arbutus Biopharma (NASDAQ:ABUS) shares rose 5% in after-hours trading despite missing Q3 analyst estimates, driven by promising clinical data for its hepatitis B treatment, imdusiran. The data showed 46% of Phase 2a patients could discontinue treatment, with 94% remaining off for over two years, and all HBV DNA positive patients in Phase 1b achieving undetectable levels after 18 weeks. The company also highlighted its strong financial position and ongoing patent litigation against Moderna and Pfizer/BioNTech.
Arbutus Biopharma (NASDAQ:ABUS) Given Buy Rating at Chardan Capital
Chardan Capital has reaffirmed a "Buy" rating for Arbutus Biopharma (NASDAQ:ABUS) with a $5.00 price target, suggesting a 10.62% upside from its current price. Despite beating EPS estimates, the biopharmaceutical company reported lower-than-expected revenue and remains unprofitable. Several institutional investors have significantly increased their stakes in the company, which currently holds a "Hold" consensus rating from MarketBeat with a $5.00 target price.
Arbutus Biopharma Faces Losses And Legal Battles This Quarter
Arbutus Biopharma reported a significant net loss and lower-than-expected revenue this quarter, alongside challenges in its Phase 2a imdusiran trial. Despite these setbacks, the company is prioritizing key drugs, trimming R&D, and continues to engage in high-stakes patent lawsuits, including recent wins against Pfizer and BioNTech. Wall Street maintains a cautious 'buy' outlook, indicating optimism about Arbutus's ability to manage its financial and legal pressures.
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Arbutus Biopharma Corporation reported its third-quarter 2025 financial results, highlighting a strong financial position with $93.7 million in cash. The company provided an update on its imdusiran clinical data, showing that 46% of Phase 2a patients discontinued treatment, with 94% remaining off treatment for up to two years. Arbutus also detailed its ongoing LNP litigation against Moderna and Pfizer/BioNTech, with key trial dates scheduled for 2026 and 2027.
Arbutus Biopharma earnings missed, revenue fell short of estimates
Arbutus Biopharma (NASDAQ: ABUS) reported third-quarter EPS of $-0.040, missing analyst estimates of $-0.033, and revenue of $529K, which fell short of the consensus estimate of $1.39M. Despite the missed earnings and revenue, Arbutus Biopharma's stock has seen a significant increase over the past 3 and 12 months. The company's financial health is rated as "fair performance" by InvestingPro.
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Arbutus Biopharma Corporation reported its third-quarter 2025 financial results, highlighting a strong financial position with $93.7 million in cash and investments. The company provided an update on its LNP litigation against Moderna and Pfizer/BioNTech, with significant trial dates scheduled. Additionally, Arbutus shared positive clinical data for its lead hepatitis B therapeutic, imdusiran (AB-729), showing that 46% of Phase 2a patients were able to discontinue all treatment and 94% of long-term follow-up patients remain off treatment for up to two years.
Lindsay Androski named CEO of Arbutus
Arbutus Biopharma Corp. appointed Lindsay Androski as CEO and replaced its entire board of directors. Androski, previously with Genevant Sciences Corp. and Roivant Sciences Ltd., will lead the company in reviewing its HBV development plans and strategic options. The new board also comprises Robert Beardsley, Anuj Hasija, Matthew Gline, Joseph Bishop, and Androski.
Arbutus Biopharma appoints new CEO and reshapes board
Arbutus Biopharma (NASDAQ: ABUS) has appointed Lindsay Androski as its new CEO and a board member, effective immediately. The company also announced a significant overhaul of its board, with four new directors joining and previous members departing, reducing the board to five members. These changes aim to refocus on advancing the company's pipeline and leveraging its LNP delivery technology through Genevant, with a temporary halt in investor meetings for strategic review.
Arbutus Biopharma Corp Reports Q2 2025 Earnings: EPS of $0.01 and Revenue of $10.7M, Surpassing Estimates
Arbutus Biopharma Corp reported strong Q2 2025 earnings, with EPS of $0.01 and revenue of $10.7 million, significantly exceeding analyst estimates due to deferred revenue recognition from reacquired rights to imdusiran. The company achieved a net income of $2.5 million, a substantial improvement from a loss in the prior year, and maintained a strong cash position while reducing operating expenses. Despite ongoing litigation, strategic developments and financial improvements highlight a positive outlook.
Arbutus Biopharma (NASDAQ:ABUS) Shows Strong Technical and Fundamental Momentum
Arbutus Biopharma (NASDAQ:ABUS) is highlighted for its strong technical and fundamental momentum, aligning with Mark Minervini's Trend Template and high-growth criteria. The stock exhibits solid technical traits, trading above key moving averages with high relative strength, and shows significant fundamental improvements in EPS and sales growth. These factors suggest a potential for continued price gains, supported by both market position and financial performance.
4 abstracts accepted: Arbutus to present imdusiran data; AB-101 named Poster of Distinction
Arbutus Biopharma (Nasdaq: ABUS) announced that four abstracts featuring data for imdusiran (AB-729) and AB-101, an oral PD-L1 inhibitor, have been accepted for presentation at The Liver Meeting® 2025. The data highlight the safety and tolerability of imdusiran, potential genotype-specific responsiveness, and increases in soluble immune biomarkers, as well as the favorable tolerability and PD-L1 receptor occupancy of AB-101, which was recognized as a Poster of Distinction. These presentations suggest progress towards a functional cure for chronic hepatitis B virus and will provide further insights into the clinical development of these candidates.
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
Arbutus Biopharma Corporation has reacquired the Greater China rights to its lead compound, imdusiran, from Qilu Pharmaceutical, following a mutual agreement to conclude their strategic partnership. This reacquisition gives Arbutus global rights to imdusiran, which has achieved functional cure in eight patients in combination therapy in Phase 2a trials. Additionally, Arbutus has formed a new Scientific Advisory Board, comprised of leading experts in chronic hepatitis B virus (cHBV) treatment, to provide strategic guidance on the company's cHBV pipeline development.
Moderna Slams Arbutus Bid to Dodge Vaccine-Patent Case Narrowing
Moderna Inc. has asked a Delaware federal judge to deny Arbutus Biopharma Corp.'s request to reconsider an order that would limit the number of patents Arbutus can assert in a lawsuit seeking royalties from Moderna’s Covid-19 vaccine. Moderna characterized Arbutus's move as "unabashedly" inconsistent and "opportunistic," accusing Arbutus and Genevant of reversing their previous stance to avoid similar limitations in their case. Arbutus argues that narrowing the patents too soon could harm its damages claim, while Moderna maintains the timing is fair and both parties face limits.
Warminster-Based Arbutus Biopharma Lays Off Over Half of Workforce, Exits Its Headquarters
Arbutus Biopharma has laid off over half of its workforce and is exiting its headquarters to conserve cash while continuing its pursuit of a hepatitis B cure. The company eliminated an additional 22 positions this month, now employing 19 people, and will incur a one-time restructuring charge of $11 million to $13 million. CEO Lindsay Androski plans to focus on advancing their new hepatitis B drug candidate, imdusiran, into a phase 2 trial.
Buckling down on HBV hopeful, Arbutus slashes more than half its workforce
Arbutus Biopharma has announced a significant workforce reduction, cutting more than half of its staff. This restructuring allows the company to focus its resources on its lead HBV therapeutic candidate, imdusiran (AB-729), along with partnered programs. The move aims to extend its cash runway into the second quarter of 2026.
Arbutus jettisons 57% of staff, ceases in-house research
Arbutus Biopharma has announced a significant restructuring, reducing its workforce by 57% and ceasing all in-house scientific research. The company will now focus its efforts on the mid-stage trials of its potential hepatitis B cure, imdusiran, retaining a core team to advance the drug into a phase 2b trial. These changes follow previous layoffs and aim to improve financial and operational efficiency, with the company also vacating its corporate headquarters.
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
Arbutus Biopharma Corporation reported its fourth quarter and year-end 2024 financial results, highlighting a strategic shift with a 57% workforce reduction and appointment of a new CFO, Tuan Nguyen. The company is re-evaluating its pipeline, particularly for its chronic hepatitis B virus (cHBV) programs, and focusing on advancing imdusiran into a Phase 2b trial. Arbutus also detailed ongoing LNP patent litigation against Moderna and Pfizer/BioNTech and presented clinical data for imdusiran and AB-101.
Genevant Sciences and Arbutus Biopharma Initiate
Genevant Sciences and Arbutus Biopharma have initiated international patent infringement lawsuits against Moderna, targeting alleged infringing activities in 30 countries. The companies are seeking monetary relief and injunctions against Moderna's Spikevax and other products for infringement of their innovative Lipid Nanoparticle (LNP) technology. These new actions expand on an existing U.S. lawsuit, reinforcing their efforts to protect their proprietary mRNA delivery system.
Can Arbutus Win Billions? Patent Fight Against Moderna's COVID Vaccine Goes Global
Genevant Sciences and Arbutus Biopharma have initiated five international patent infringement lawsuits against Moderna across 30 countries, alleging unauthorized use of their lipid nanoparticle (LNP) technology in Spikevax® and mRESVIA® products. They are seeking monetary damages and injunctions, supported by evidence from testing commercial Moderna samples. This global expansion follows ongoing U.S. litigation, with a jury trial scheduled for September 2025, significantly intensifying pressure on Moderna.
Biogen names new CFO, CMO
Biogen (NASDAQ:BIIB) announced leadership changes, with Michael McDonnell retiring as CFO and Robin Kramer succeeding him. The company also named Daniel Quirk as its new CMO and head of medical affairs. Additionally, Ottimo Pharma Ltd. made several key appointments, including David Epstein as chair and CEO.
RNA-Based Therapeutics Market to Grow by USD 1.27 Billion (2024-2028) Due to Increased Investment and Funding, AI Trends Impacting Revenue - Technavio
The RNA-Based Therapeutics Market is projected to grow by USD 1.26 billion from 2024-2028, driven by increased investment, funding, and collaborations. Despite challenges posed by high development costs, AI-powered strategies and strategic partnerships are advancing RNA therapies for various diseases. Key players like Alnylam Pharmaceuticals, Moderna, and BioNTech are contributing to this growth by focusing on mRNA therapeutics, antisense oligonucleotides, and RNA interference technologies.
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Arbutus Biopharma (ABUS) reported Q2 2024 financial results, including revenue of $1.7 million and a net loss of $19.8 million. The company announced a strategic shift, prioritizing imdusiran's Phase 2b development, discontinuing HBV discovery efforts, and reducing its workforce by 40%, which extends its cash runway into Q4 2026. Positive Phase 2a data for imdusiran suggests potential for a functional HBV cure, driven by 33% of patients achieving undetectable HBsAg after 48 weeks of treatment.
Moderna shares fall after judge sides with Arbutus in patent fight
Moderna's shares fell 4% after a U.S. judge sided with Arbutus in a patent infringement lawsuit concerning Moderna's COVID-19 vaccine. The judge's "claim construction order" strengthened Arbutus' case regarding the patented lipid nanoparticles used in the vaccine. This ruling is a significant development ahead of the trial set for April next year.
Arbutus Biopharma CEO to retire as company cuts workforce by 24%
Arbutus Biopharma's CEO, William Collier, is set to retire at the end of the year. The company is also implementing a 24% workforce reduction. These changes follow Arbutus's decision in September to narrow its research focus to conserve cash.
Arbutus files patent lawsuit against Pfizer/BioNTech over COVID vaccines
Arbutus Biopharma has sued Pfizer Inc and BioNTech SE, claiming their mRNA COVID-19 vaccines infringe five of Arbutus' patents related to lipid nanoparticle (LNP) delivery technology. Arbutus and its licensee Genevant Sciences are seeking damages, including reasonable royalties. This lawsuit follows a similar one filed by Arbutus against Moderna Inc last year and comes amidst other patent infringement claims against Pfizer and BioNTech regarding their COVID-19 vaccines.
Arbutus Announces Resignation of Board Member
Arbutus Biopharma Corporation announced the resignation of Dr. Tram Tran from its Board of Directors, effective February 26, 2023. Dr. Tran is transitioning into public service, which precludes her participation on pharmaceutical and biotechnology boards. The company expressed gratitude for her contributions and will immediately begin a search for a new independent board member.
4 Penny Stocks That Are Trending on Reddit Right Now and Why
This article discusses four penny stocks - Ensysce Biosciences Inc. (ENSC), Vyne Therapeutics Inc. (VYNE), Arbutus Biopharma Corp. (ABUS), and Genius Brands International Inc. (GNUS) - that are trending on Reddit in December 2021. It highlights reasons for their recent movements, including clinical trial results, analyst valuations, and corporate announcements, primarily focusing on the biotech sector. The author advises investors to conduct thorough research before investing in these highly speculative stocks.
Arbutus Sells Part of its ONPATTRO™ (patisiran) Royalty Interest to OMERS
Arbutus Biopharma Corporation has sold a portion of its royalty interest in ONPATTRO™ (patisiran) to OMERS for $20 million in gross proceeds. This strategic move provides Arbutus with non-dilutive capital, extending its financial runway while allowing it to retain significant downstream royalty economics from the Alnylam LNP license agreement and a separate royalty from Acuitas Therapeutics. OMERS will receive royalties until it reaches $30 million, after which the full entitlement will revert to Arbutus.
Vivek Ramaswamy’s Roivant backs Arbutus’ hepatitis B program
Vivek Ramaswamy's Roivant Sciences has invested an additional $116 million in Arbutus Biopharma to support its hepatitis B (HBV) drug development program, following positive phase 2 data for Arbutus's lead candidate ARB-1467. This increased stake aims to accelerate the development of Arbutus's HBV pipeline and other programs, providing critical resources for the Canadian biotech. The deal also helps Roivant move past a recent setback with its Alzheimer's unit and highlights the growing market potential for an HBV cure, estimated to be worth billions.
Video: CPHS Graduate Honored as Campbell University Distinguished Alumni
William T. Symonds, PharmD ’91, has been honored with the Campbell University Distinguished Alumni Award by the Campbell University Alumni Association. Symonds has a distinguished career in clinical research, holding senior positions at Roivant Sciences, Inc., Gilead Sciences, Inc., and Pharmasset, Inc., and previously at GlaxoSmithKline. He is also a 1991 Doctor of Pharmacy graduate of Campbell University and serves on the College of Pharmacy & Health Sciences’ Dean’s Board of Advisors.
